
Dr Hussein Al-Ali
Hussein is a cancer biologist working between academic research and industry. His research focuses on detecting circulating tumour cells and on antibody-based cancer therapeutics, taking new treatments from early laboratory testing towards the clinic.
- PhD from Brunel University London, on DNA damage detection and cancer therapy response
- Long-standing translational collaborations with biotech partners, including Medannex (anti-annexin-A1 antibody MDX-124) and aTen Therapeutics
- Developed imaging flow cytometry methods for sensitive detection of DNA damage
- Led the company's Cambridge UK Biopharmaceutical R&D Service Platform, approved under Hangzhou's Dinghu talent programme in 2025
- Vice-Chancellor's Awards for research impact and industry engagement
- Circulating tumour cells
- Therapeutic antibodies
- Imaging flow cytometry
- UK–China partnerships

